ALDX Quote, Financials, Valuation and Earnings

Edgewise Therapeutics has a net margin of -- compared to Aldeyra Therapeutics's net margin of --. Aldeyra Therapeutics's return on equity of -- beat Edgewise Therapeutics's return on equity of --.

Aldeyra Therapeutics has a consensus price target of $8.29, signalling upside risk potential of 273.23%. On the other hand Edgewise Therapeutics has an analysts' consensus of $39.00 which suggests that it could grow by 174.46%. Given that Aldeyra Therapeutics has higher upside potential than Edgewise Therapeutics, analysts believe Aldeyra Therapeutics is more attractive than Edgewise Therapeutics.

Aldeyra Therapeutics has a beta of 0.917, which suggesting that the stock is 8.339% less volatile than S&P 500. In comparison Edgewise Therapeutics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Aldeyra Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Edgewise Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Aldeyra Therapeutics pays -- of its earnings as a dividend. Edgewise Therapeutics pays out -- of its earnings as a dividend.

Aldeyra Therapeutics quarterly revenues are --, which are smaller than Edgewise Therapeutics quarterly revenues of --. Aldeyra Therapeutics's net income of -$9.9M is higher than Edgewise Therapeutics's net income of -$40.8M. Notably, Aldeyra Therapeutics's price-to-earnings ratio is -- while Edgewise Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aldeyra Therapeutics is -- versus -- for Edgewise Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

ICU Medical has a net margin of -- compared to Aldeyra Therapeutics's net margin of -2.56%. Aldeyra Therapeutics's return on equity of -- beat ICU Medical's return on equity of -4.64%.

Aldeyra Therapeutics has a consensus price target of $8.29, signalling upside risk potential of 273.23%. On the other hand ICU Medical has an analysts' consensus of $186.20 which suggests that it could grow by 44.35%. Given that Aldeyra Therapeutics has higher upside potential than ICU Medical, analysts believe Aldeyra Therapeutics is more attractive than ICU Medical.

Aldeyra Therapeutics has a beta of 0.917, which suggesting that the stock is 8.339% less volatile than S&P 500. In comparison ICU Medical has a beta of 0.870, suggesting its less volatile than the S&P 500 by 12.976%.

Aldeyra Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ICU Medical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Aldeyra Therapeutics pays -- of its earnings as a dividend. ICU Medical pays out -- of its earnings as a dividend.

Aldeyra Therapeutics quarterly revenues are --, which are smaller than ICU Medical quarterly revenues of $604.7M. Aldeyra Therapeutics's net income of -$9.9M is higher than ICU Medical's net income of -$15.5M. Notably, Aldeyra Therapeutics's price-to-earnings ratio is -- while ICU Medical's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aldeyra Therapeutics is -- versus 1.30x for ICU Medical. Usually stocks with elevated PS ratios are considered overvalued.

RxSight has a net margin of -- compared to Aldeyra Therapeutics's net margin of -21.61%. Aldeyra Therapeutics's return on equity of -- beat RxSight's return on equity of -10.39%.

Aldeyra Therapeutics has a consensus price target of $8.29, signalling upside risk potential of 273.23%. On the other hand RxSight has an analysts' consensus of $21.18 which suggests that it could grow by 35.09%. Given that Aldeyra Therapeutics has higher upside potential than RxSight, analysts believe Aldeyra Therapeutics is more attractive than RxSight.

Aldeyra Therapeutics has a beta of 0.917, which suggesting that the stock is 8.339% less volatile than S&P 500. In comparison RxSight has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Aldeyra Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. RxSight offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Aldeyra Therapeutics pays -- of its earnings as a dividend. RxSight pays out -- of its earnings as a dividend.

Aldeyra Therapeutics quarterly revenues are --, which are smaller than RxSight quarterly revenues of $37.9M. Aldeyra Therapeutics's net income of -$9.9M is lower than RxSight's net income of -$8.2M. Notably, Aldeyra Therapeutics's price-to-earnings ratio is -- while RxSight's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aldeyra Therapeutics is -- versus 4.21x for RxSight. Usually stocks with elevated PS ratios are considered overvalued.

Sarepta Therapeutics has a net margin of -- compared to Aldeyra Therapeutics's net margin of -60.08%. Aldeyra Therapeutics's return on equity of -- beat Sarepta Therapeutics's return on equity of -20.94%.

Aldeyra Therapeutics has a consensus price target of $8.29, signalling upside risk potential of 273.23%. On the other hand Sarepta Therapeutics has an analysts' consensus of $89.96 which suggests that it could grow by 137.36%. Given that Aldeyra Therapeutics has higher upside potential than Sarepta Therapeutics, analysts believe Aldeyra Therapeutics is more attractive than Sarepta Therapeutics.

Aldeyra Therapeutics has a beta of 0.917, which suggesting that the stock is 8.339% less volatile than S&P 500. In comparison Sarepta Therapeutics has a beta of 0.846, suggesting its less volatile than the S&P 500 by 15.365%.

Aldeyra Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sarepta Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Aldeyra Therapeutics pays -- of its earnings as a dividend. Sarepta Therapeutics pays out -- of its earnings as a dividend.

Aldeyra Therapeutics quarterly revenues are --, which are smaller than Sarepta Therapeutics quarterly revenues of $744.9M. Aldeyra Therapeutics's net income of -$9.9M is higher than Sarepta Therapeutics's net income of -$447.5M. Notably, Aldeyra Therapeutics's price-to-earnings ratio is -- while Sarepta Therapeutics's PE ratio is 20.50x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aldeyra Therapeutics is -- versus 1.89x for Sarepta Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.